1. Home
  2. BATL vs MRKR Comparison

BATL vs MRKR Comparison

Compare BATL & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Battalion Oil Corporation

BATL

Battalion Oil Corporation

HOLD

Current Price

$1.57

Market Cap

27.1M

Sector

Energy

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.31

Market Cap

22.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BATL
MRKR
Founded
1987
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.1M
22.5M
IPO Year
2004
2010

Fundamental Metrics

Financial Performance
Metric
BATL
MRKR
Price
$1.57
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
12.4M
65.1K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
42.56
33.61
EPS
N/A
N/A
Revenue
$166,043,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.81
52 Week High
$29.70
$2.46

Technical Indicators

Market Signals
Indicator
BATL
MRKR
Relative Strength Index (RSI) 48.86 38.05
Support Level $1.06 $1.17
Resistance Level $2.42 $1.54
Average True Range (ATR) 0.25 0.08
MACD 0.05 -0.03
Stochastic Oscillator 28.99 2.27

Price Performance

Historical Comparison
BATL
MRKR

About BATL Battalion Oil Corporation

Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: